Acuta Capital Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Acuta Capital Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,000	Closed	-$655K	–	46
2023 Q1	$655K	Hold	6,000	–	–	0.48%	28
2022 Q4	$683K	Buy	6,000 +2,000	+50%	+$166K	0.42%	30
2022 Q3	$248K	Sell	4,000 -31,888	-89%	-$2.23M	0.11%	37
2022 Q2	$2.86M	Buy	35,888 +2,688	+8%	+$255K	1.59%	20
2022 Q1	$3.49M	Buy	+33,200	New	+$3.24M	1.63%	24
2015 Q1	–	Sell	-167,491	Closed	-$2.16M	–	74
2014 Q4	$2.16M	Buy	+167,491	New	+$2.1M	1.46%	20

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acuta Capital Partners's HZNP Position: Q2 2023 in Review

Acuta Capital Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 6,000 shares — an estimated $655K sold.

Acuta Capital Partners first reported a position in HZNP in Q4 2014 and held it in 6 quarters. The position peaked at $3.49M in Q1 2022. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Acuta Capital Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Acuta Capital Partners sold 6,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $655K.
Acuta Capital Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and held it in 6 quarters.
Acuta Capital Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.49M in Q1 2022.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Acuta Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.